Do Young Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Do Young Kim has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Sung Hea Kim
Division of Cardiology, Department of Medicine, Konkuk University Medical Center, Seoul 05030, Republic of Korea
3 shared publications Jae Hyuk Choi
Cardiovascular Center, Hallym University Dongtan Sacred Heart, Hwaseong, Korea
2 shared publications- Kyu-Hyung Ryu
Division of Cardiology, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Korea
2 shared publications - Mi-Hyang Jung
Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
2 shared publications Seongwoo Han
Cardiovascular Center, Hallym University Dongtan Sacred Heart, Hwaseong, Korea
2 shared publications- Dae Young Cheon
Division of Cardiology, Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea
1 shared publication
Latest Publications
- Open Access
- 1 January 2027
- Published by XMLink in Journal of Korean Medical Science
- Vol. 42
Efficacy and Safety of Direct Oral Anticoagulants for Stroke Prevention in Korean Patients With Atrial Fibrillation
Kim DY, et al. J Korean Med Sci. 2027 Jan;42:e28. https://doi.org/10.3346/jkms.2027.42.e28
- 1 January 2027
- Published by XMLink in Journal of Korean Medical Science
- Vol. 42
Open AccessEfficacy and Safety of Direct Oral Anticoagulants for Stroke Prevention in Korean Patients With Atrial Fibrillation
Kim DY, et al. J Korean Med Sci. 2027 Jan;42:e28. https://doi.org/10.3346/jkms.2027.42.e28
- Open Access
- 1 January 2026
- Published by XMLink in Clinical Hypertension
- Vol. 32 (1)
Evaluation of guideline adherence to hypertension-mediated organ damage screening in Korean patients with hypertension: results from the Korean Registry of Target Organ Damage in Hypertension (KorHR)
Kim DY, et al. Clin Hypertens. 2026 ;32(1):e11. https://doi.org/10.5646/ch.2026.32.e11
- 1 January 2026
- Published by XMLink in Clinical Hypertension
- Vol. 32 (1)
Open AccessEvaluation of guideline adherence to hypertension-mediated organ damage screening in Korean patients with hypertension: results from the Korean Registry of Target Organ Damage in Hypertension (KorHR)
Kim DY, et al. Clin Hypertens. 2026 ;32(1):e11. https://doi.org/10.5646/ch.2026.32.e11
- Open Access
- 14 October 2022
- Published by Korean Society of Heart Failure in International Journal of Heart Failure
- Vol. 4 (4) , 205-208
Acute Myocarditis After COVID-19 Vaccination
Cheon DY, et al. Int J Heart Fail. 2022 Oct;4:e19. https://doi.org/10.36628/ijhf.2022.0019
- 14 October 2022
- Published by Korean Society of Heart Failure in International Journal of Heart Failure
- Vol. 4 (4) , 205-208
Open AccessAcute Myocarditis After COVID-19 Vaccination
Cheon DY, et al. Int J Heart Fail. 2022 Oct;4:e19. https://doi.org/10.36628/ijhf.2022.0019
- Open Access
- 17 August 2021
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 10 (16) , e021931
Development and Validation of a Risk Score Model for Predicting the Cardiovascular Outcomes After Breast Cancer Therapy: The CHEMO‐RADIAT Score
Background: Cardiovascular disease is an important cause of mortality among survivors of breast cancer (BC). We developed a prediction model for major adverse cardiovascular events after BC therapy, which is based on conventional and BC treatment‐related cardiovascular risk factors. Methods and Results: The cohort of the study consisted of 1256 Asian female patients with BC from 4 medical centers in Korea and was randomized in a 1:1 ratio into the derivation and validation cohorts. The outcome measures comprised cardiovascular mortality, myocardial infarction, congestive heart failure, and transient ischemic attack/stroke. To correct overfitting, a penalized Cox proportional hazards regression was performed with a cross‐validation approach. Number of cardiovascular diseases (myocardial infarction, peripheral artery disease, heart failure, and transient ischemic attack/stroke), number of baseline cardiovascular risk factors (hypertension, age ≥60, body mass index ≥30 kg/m 2 , estimated glomerular filtration rate 2 , dyslipidemia, and diabetes mellitus), radiation to the left breast, and anthracycline dose per 100 mg/m 2 were included in the risk prediction model. The time‐dependent C‐indices at 3 and 7 years after BC diagnosis were 0.876 and 0.842, respectively, in the validation cohort. Conclusions: A prediction score model, including BC treatment‐related risk factors and conventional risk factors, was developed and validated to predict major adverse cardiovascular events in patients with BC. The CHEMO‐RADIAT (congestive heart failure, hypertension, elderly, myocardial infarction/peripheral artery occlusive disease, obesity, renal failure, abnormal lipid profile, diabetes mellitus, irradiation of the left breast, anthracycline dose, and transient ischemic attack/stroke) score may provide overall cardiovascular risk stratification in survivors of BC and can assist physicians in multidisciplinary decision‐making regarding the BC treatment.
- 17 August 2021
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 10 (16) , e021931
Open AccessDevelopment and Validation of a Risk Score Model for Predicting the Cardiovascular Outcomes After Breast Cancer Therapy: The CHEMO‐RADIAT Score
Background: Cardiovascular disease is an important cause of mortality among survivors of breast cancer (BC). We developed a prediction model for major adverse cardiovascular events after BC therapy, which is based on conventional and BC treatment‐related cardiovascular risk factors. Methods and Results: The cohort of the study consisted of 1256 Asian female patients with BC from 4 medical centers in Korea and was randomized in a 1:1 ratio into the derivation and validation cohorts. The outcome measures comprised cardiovascular mortality, myocardial infarction, congestive heart failure, and transient ischemic attack/stroke. To correct overfitting, a penalized Cox proportional hazards regression was performed with a cross‐validation approach. Number of cardiovascular diseases (myocardial infarction, peripheral artery disease, heart failure, and transient ischemic attack/stroke), number of baseline cardiovascular risk factors (hypertension, age ≥60, body mass index ≥30 kg/m 2 , estimated glomerular filtration rate 2 , dyslipidemia, and diabetes mellitus), radiation to the left breast, and anthracycline dose per 100 mg/m 2 were included in the risk prediction model. The time‐dependent C‐indices at 3 and 7 years after BC diagnosis were 0.876 and 0.842, respectively, in the validation cohort. Conclusions: A prediction score model, including BC treatment‐related risk factors and conventional risk factors, was developed and validated to predict major adverse cardiovascular events in patients with BC. The CHEMO‐RADIAT (congestive heart failure, hypertension, elderly, myocardial infarction/peripheral artery occlusive disease, obesity, renal failure, abnormal lipid profile, diabetes mellitus, irradiation of the left breast, anthracycline dose, and transient ischemic attack/stroke) score may provide overall cardiovascular risk stratification in survivors of BC and can assist physicians in multidisciplinary decision‐making regarding the BC treatment.
- Open Access
- 1 January 2019
- Published by The Korean Society of Cardiology in Korean Circulation Journal
- Vol. 49 (9) , 808-817
Tachycardia induced Cardiomyopathy
Recent studies on radiofrequency catheter ablation (RFCA) in atrial fibrillation show its effectiveness in heart failure (HF) patients; hence, tachycardia-induced cardiomyopathy (T-CMP) is gaining attention. Tachycardia-mediated cardiomyopathy is a reversible left ventricular (LV) dysfunction, which can be induced by any tachyarrhythmia. Early recognition of T-CMP with appropriate treatment of the arrhythmia culprit will lead to the recovery of LV function. Patients with tachycardia and LV dysfunction should be suspected of having T-CMP, with or without established etiology of HF, because T-CMP may present by itself or contribute as a co-existent component. Therapeutic options include rate control, anti-arrhythmic drugs, or catheter ablation. Unlike in animal models, clinical data on human T-CMP is limited. Hence, future research should be more focused on tachyarrhythmia-induced cardiomyopathy as its burden is increasing.
- 1 January 2019
- Published by The Korean Society of Cardiology in Korean Circulation Journal
- Vol. 49 (9) , 808-817
Open AccessTachycardia induced Cardiomyopathy
Recent studies on radiofrequency catheter ablation (RFCA) in atrial fibrillation show its effectiveness in heart failure (HF) patients; hence, tachycardia-induced cardiomyopathy (T-CMP) is gaining attention. Tachycardia-mediated cardiomyopathy is a reversible left ventricular (LV) dysfunction, which can be induced by any tachyarrhythmia. Early recognition of T-CMP with appropriate treatment of the arrhythmia culprit will lead to the recovery of LV function. Patients with tachycardia and LV dysfunction should be suspected of having T-CMP, with or without established etiology of HF, because T-CMP may present by itself or contribute as a co-existent component. Therapeutic options include rate control, anti-arrhythmic drugs, or catheter ablation. Unlike in animal models, clinical data on human T-CMP is limited. Hence, future research should be more focused on tachyarrhythmia-induced cardiomyopathy as its burden is increasing.
- Open Access
- 1 January 2018
- Published by The Korean Society of Cardiology in Korean Circulation Journal
- Vol. 48 (5) , 433-434
Oral Anticoagulants for Atrial Fibrillation Patients with Active Cancer
- 1 January 2018
- Published by The Korean Society of Cardiology in Korean Circulation Journal
- Vol. 48 (5) , 433-434
Open AccessOral Anticoagulants for Atrial Fibrillation Patients with Active Cancer